Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker
Status:
Completed
Trial end date:
2015-03-17
Target enrollment:
Participant gender:
Summary
This is a study to investigate the safety and tolerability of the partial A1 agonist
BAY1067197 in patients with chronic heart failure. BAY1067197 will be applied as a single
dose of 30 mg in addition to standard therapy including a beta-blocker. The aim of the study
is to assess if a single oral dose of 30 mg BAY1067197 is well tolerated when given on top of
standard therapy for heart failure, particularly ß-blocker treatment.